ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Peter Ho, PhD, Director of Business Development, will present a company overview at 2:00 pm ET and participate in a panel discussion on advances in immunotherapy for glioma at 2:45 pm ET at the 3 rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference on Thursday, October 4, 2012, at the New York Academy of Medicine. A live and archived webcast of the company's presentation at the conference hosted by MD Becker Partners LLC will be available at www.regonline.com/mdb2012. John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the 11 th Annual BIO Investor Forum on October 10, 2012 at 3:00 pm PT at the Palace Hotel, San Francisco, CA. To access the live audio webcast of the BIO Investor Forum presentation, please log on through a link located in the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Investors, Webcasts & Presentations tab. A replay of the webcasts will be available one hour after the conclusion of the live events. About ImmunoCellular Therapeutics, Ltd. ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about ImmunoCellular, please visit www.imuc.com.